|
|
Blood, 1 October 2006, Vol. 108, No. 7, pp. 2416-2419.
Prepublished online as a Blood First Edition Paper on June 20, 2006; DOI 10.1182/blood-2006-02-003582.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Brief report
CCAAT/enhancer binding proteins alpha and epsilon cooperate with all-trans retinoic acid in therapy but differ in their antileukemic activities
Young-Jin Lee,
Letetia C. Jones,
Nikolai A. Timchenko,
Danilo Perrotti,
Daniel G. Tenen, and
Scott C. Kogan
From the Department of Laboratory Medicine and Comprehensive Cancer Center, University of California San Francisco; Huffington Center on Aging and Department of Pathology, Baylor College of Medicine, Houston, TX; Department of Molecular Virology, Immunology and Medical Genetics and the Comprehensive Cancer Center, The Ohio State University, Columbus; and Harvard Institutes of Medicine, Harvard Medical School, Boston, MA.
CCAAT/enhancer binding proteins (C/EBPs) play critical roles in myelopoiesis. Dysregulation of these proteins likely contributes to the pathogenesis of myeloid disorders characterized by a block in granulopoiesis. In one such disease, acute promyelocytic leukemia (APL), a promyelocytic leukemia–retinoic acid receptor  (PML-RAR) fusion protein is expressed as a result of a t(15;17) chromosomal translocation. Treatment of PML-RAR leukemic cells with all-trans retinoic acid (ATRA) causes them to differentiate into mature neutrophils, an effect thought to be mediated by C/EBPs. In this study, we assess the potential for cooperativity between increased C/EBP activity and ATRA therapy. We demonstrate that although both C/EBP and C/EBP can significantly prolong survival in a mouse model of APL, they are not functionally equivalent in this capacity. We also show that forced expression of C/EBP or C/EBP in combination with ATRA treatment has a synergistic effect on survival of leukemic mice compared with either therapy alone.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. K. Burnett, R. K. Hills, C. Green, S. Jenkinson, K. Koo, Y. Patel, C. Guy, A. Gilkes, D. W. Milligan, A. H. Goldstone, et al.
The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA
Blood,
February 4, 2010;
115(5):
948 - 956.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. C. Guibal, M. Alberich-Jorda, H. Hirai, A. Ebralidze, E. Levantini, A. Di Ruscio, P. Zhang, B. A. Santana-Lemos, D. Neuberg, A. J. Wagers, et al.
Identification of a myeloid committed progenitor as the cancer-initiating cell in acute promyelocytic leukemia
Blood,
December 24, 2009;
114(27):
5415 - 5425.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Pabst and B. U. Mueller
Complexity of CEBPA Dysregulation in Human Acute Myeloid Leukemia
Clin. Cancer Res.,
September 1, 2009;
15(17):
5303 - 5307.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Koschmieder, B. Halmos, E. Levantini, and D. G. Tenen
Dysregulation of the C/EBP{alpha} Differentiation Pathway in Human Cancer
J. Clin. Oncol.,
February 1, 2009;
27(4):
619 - 628.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
